Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis
- PMID: 28438547
- DOI: 10.1016/j.diabet.2017.03.004
Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis
Abstract
Background: The association between metformin and colorectal cancer (CRC) has rarely been investigated in Asian populations.
Methods: This retrospective cohort study included patients with newly diagnosed type 2 diabetes during 1999-2005, recruited from Taiwan's National Health Insurance database. A total of 169,601 patients (original cohort: 153,270 ever-users and 16,331 never-users of metformin) and a subgroup of 1:1 propensity-score-matched pairs of 16,331 ever-users and 16,331 never-users (matched cohort) were followed up to 31 December 2011. Cox regression was constructed with the inverse probability of treatment-weighting, using propensity scores, and was used to estimate hazard ratios (HRs).
Results: In the original cohort, the incidence of CRC was 242.9 and 480.9 per 100,000 person-years, respectively, in ever- and never-users. The overall HR [0.50, 95% confidence interval (CI): 0.45-0.56] suggested a significantly lower risk in metformin users, while compared with never-users, the HR (95% CI) for the first (<27.1 months), second (27.1-58.1 months) and third (>58.1 months) tertiles of cumulative duration of metformin therapy was 0.86 (0.76-0.98), 0.51 (0.45-0.59) and 0.26 (0.23-0.30), respectively. Analyses in the matched cohort showed similar findings with an overall HR of 0.62 (0.53-0.74), and a tertile analysis HR of 1.02 (0.81-1.28), 0.70 (0.56-0.89) and 0.32 (0.23-0.43), respectively. Re-analyses using more stringent diagnoses of CRC and cumulative duration as a continuous variable have consistently supported a protective effect with metformin use.
Conclusion: Metformin is associated with a lower frequency of CRC.
Keywords: Colorectal cancer; Diabetes mellitus; Metformin; Taiwan.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone.Aging Dis. 2020 May 9;11(3):658-667. doi: 10.14336/AD.2019.0621. eCollection 2020 May. Aging Dis. 2020. PMID: 32489710 Free PMC article. Review.
-
Metformin and lung cancer risk in patients with type 2 diabetes mellitus.Oncotarget. 2017 Jun 20;8(25):41132-41142. doi: 10.18632/oncotarget.17066. Oncotarget. 2017. PMID: 28456789 Free PMC article.
-
Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.Aging (Albany NY). 2016 Aug;8(8):1636-49. doi: 10.18632/aging.101019. Aging (Albany NY). 2016. PMID: 27587088 Free PMC article.
-
Metformin use and cervical cancer risk in female patients with type 2 diabetes.Oncotarget. 2016 Sep 13;7(37):59548-59555. doi: 10.18632/oncotarget.10934. Oncotarget. 2016. PMID: 27486978 Free PMC article.
-
Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis.J Diabetes Res. 2017;2017:5063239. doi: 10.1155/2017/5063239. Epub 2017 Feb 8. J Diabetes Res. 2017. PMID: 28271076 Free PMC article. Review.
Cited by
-
Metformin and Risk of Hypertension in Taiwanese Patients With Type 2 Diabetes Mellitus.J Am Heart Assoc. 2018 Jun 28;7(13):e008860. doi: 10.1161/JAHA.118.008860. J Am Heart Assoc. 2018. PMID: 29954747 Free PMC article.
-
Metformin and the Risk of Dementia in Type 2 Diabetes Patients.Aging Dis. 2019 Feb 1;10(1):37-48. doi: 10.14336/AD.2017.1202. eCollection 2019 Feb. Aging Dis. 2019. PMID: 30705766 Free PMC article.
-
Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone.Aging Dis. 2020 May 9;11(3):658-667. doi: 10.14336/AD.2019.0621. eCollection 2020 May. Aging Dis. 2020. PMID: 32489710 Free PMC article. Review.
-
Metformin Use Was Associated With Reduced Risk of Incidental Sjögren's Syndrome in Patients With Type 2 Diabetes: A Population-Based Cohort Study.Front Med (Lausanne). 2022 Jan 12;8:796615. doi: 10.3389/fmed.2021.796615. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35096887 Free PMC article.
-
The causal relationship between anti-diabetic drugs and gastrointestinal disorders: a drug-targeted mendelian randomization study.Diabetol Metab Syndr. 2024 Jun 26;16(1):141. doi: 10.1186/s13098-024-01359-z. Diabetol Metab Syndr. 2024. PMID: 38918852 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical